Abivax S.A. Stock
Price
Target price
€71.40
€71.40
1.130%
0.8
1.130%
-
16:20 / Tradegate
WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Abivax S.A. Stock
Abivax S.A. gained 1.130% today.
Our community identified positive and negative aspects for Abivax S.A. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Abivax S.A. stock. On the other hand our users think that "Valuation (undervalued/overvalued)" could be a problem in the future.
Pros and Cons of Abivax S.A. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | 1.130% | - | - | - | - | - | - |
| Valneva SE | 0.120% | 14.266% | 39.773% | 90.797% | 131.426% | -4.269% | -28.076% |
| Nanobiotix | 0.120% | 26.814% | 130.372% | 248.958% | 446.196% | 346.667% | 158.521% |
| Transgene S.A. | -0.450% | 1.357% | -4.681% | 1.818% | 63.504% | -39.328% | -6.822% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review